Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity
暂无分享,去创建一个
Yun Ji | Luis Sanchez-Perez | Douglas C. Palmer | Steven A. Rosenberg | S. Kern | W. Leonard | S. Rosenberg | R. Danner | P. Muranski | C. Logun | N. Restifo | L. Gattinoni | D. Palmer | Rosanne Spolski | Christian S. Hinrichs | Zhiya Yu | L. Cassard | Robert L. Danner | Zachary A Borman | Nicholas P. Restifo | Zachary A. Borman | Lydie Cassard | Luca Gattinoni | Rosanne Spolski | Zhiya Yu | Pawel Muranski | Steven J. Kern | Carol Logun | Robert N. Reger | Warren J. Leonard | R. Reger | L. Sanchez-Perez | Yun Ji | C. Hinrichs
[1] Hao Liu,et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.
[2] D. Voehringer,et al. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). , 2002, Blood.
[3] P. Marrack,et al. Identification of two major types of age-associated CD8 clonal expansions with highly divergent properties , 2008, Proceedings of the National Academy of Sciences.
[4] V. Bronte,et al. Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.
[5] N. Restifo,et al. Programming CD8+ T cells for effective immunotherapy. , 2006, Current opinion in immunology.
[6] T. Waldmann,et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[7] C. Liu,et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. , 2008, The Journal of clinical investigation.
[8] F. Sallusto,et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.
[9] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[10] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[11] Mike Gough,et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.
[12] T. Waldmann,et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[13] S. Kaech,et al. Expression of IL-7 receptor α is necessary but not sufficient for the formation of memory CD8 T cells during viral infection , 2007, Proceedings of the National Academy of Sciences.
[14] P. Hanley,et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. , 2009, Blood.
[15] E. Wherry,et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin , 2005, Nature Immunology.
[16] R. Ahmed,et al. Differentiation of memory B and T cells. , 2006, Current opinion in immunology.
[17] S. Rosenberg,et al. Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.
[18] V. Appay,et al. CD8+ T cell efficacy in vaccination and disease , 2008, Nature Medicine.
[19] B. Thiers,et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2008 .
[20] P. Marrack,et al. CD4 memory T cells divide poorly in response to antigen because of their cytokine profile , 2008, Proceedings of the National Academy of Sciences.
[21] C. June,et al. Adoptive T cell therapy for cancer in the clinic. , 2007, The Journal of clinical investigation.
[22] P. Muranski,et al. Type 17 CD8+ T cells display enhanced antitumor immunity. , 2009, Blood.
[23] P. Marrack,et al. CD4 memory T cells: what are they and what can they do? , 2009, Seminars in immunology.
[24] L. Picker,et al. Addendum: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge , 2011, Nature Medicine.
[25] S. J. Griffiths,et al. KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. , 2009, Blood.
[26] Chung-Che Chang,et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. , 2007, Blood.
[27] T. Schumacher,et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. , 2007, Blood.
[28] S. Rosenberg,et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] T. Mosmann,et al. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. , 1995, Immunity.
[30] W. Leonard,et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. , 2008, Blood.
[31] Victor Appay,et al. Lessons from the study of T-cell differentiation in persistent human virus infection. , 2004, Seminars in immunology.
[32] S. Rosenberg,et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. , 2008, Human gene therapy.
[33] C. June,et al. Principles of adoptive T cell cancer therapy. , 2007, The Journal of clinical investigation.
[34] S. Rosenberg,et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.
[35] C. Turtle,et al. Adoptive transfer of virus-specific and tumor-specific T cell immunity. , 2009, Current opinion in immunology.
[36] S. Rosenberg,et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity , 2008, Proceedings of the National Academy of Sciences.
[37] P. Hwu,et al. Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy , 2007, Clinical Cancer Research.
[38] M. Shinohara,et al. Analysis of regulatory CD8 T cells in Qa-1-deficient mice , 2004, Nature Immunology.
[39] W. Linehan,et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.
[40] S. Rosenberg,et al. Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.
[41] P. Muranski,et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.
[42] Mario Roederer,et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.
[43] E. Wherry,et al. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. , 2007, Immunity.